Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Kava root (Piper methysticum) contains six major kavalactones—kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin—that modulate GABA-A receptors to reduce anxiety. These compounds inhibit sodium channels, cyclooxygenase enzymes, and monoamine oxidase B while activating Nrf2 antioxidant pathways.
Reported Benefits (Provisional)
Origin & History
Kava Root (Piper methysticum) is a perennial shrub native to the volcanic islands of the South Pacific, including Vanuatu, Fiji, Tonga, and Samoa. Thriving in warm, humid climates, the root of Kava is traditionally valued for its kavalactone content, which contributes to its calming and stress-reducing properties.
Research Narrative (Provisional)
Extensive scientific research, including randomized controlled trials and meta-analyses, supports Kava Root's efficacy in reducing anxiety and improving sleep quality. Studies confirm the anxiolytic and sedative effects of kavalactones. However, concerns regarding potential liver toxicity with long-term or high-dose use have led to regulatory scrutiny, emphasizing the importance of responsible sourcing and dosage.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Kavalactones (e.g., Kavain, Dihydrokavain, Methysticin, Yangonin) - Flavonoids - Alkaloids - Vitamin C - Essential Oils
Reported Mechanism (Provisional)
Kavalactones modulate GABA-A receptors in a flumazenil-insensitive manner, with kavain providing primary anxiolytic effects. These compounds inhibit sodium channels in hippocampal neurons, suppress COX-I and COX-II enzymes, and inhibit monoamine oxidase B with low μM potency. Methysticin, kavain, and yangonin activate the Nrf2 pathway in neuronal cells, while flavokavains suppress JNK/p38 MAPK signaling and TNFα-induced nuclear factor κB activation.
Clinical Narrative (Provisional)
Clinical evidence for kava's efficacy relies primarily on older randomized controlled trials and meta-analyses showing anxiolytic effects, though current research lacks comprehensive human trial data with specific quantified outcomes. Laboratory studies demonstrate that kavalactones at 25 μM concentrations inhibit intracellular calcium influxes in lung cancer cells, and flavokavain B at 30 μg/mL stimulates immune cell proliferation in animal models. Human studies confirm that kava reduces CYP2E1 expression by approximately 40% in healthy volunteers. The strength of clinical evidence for therapeutic applications remains limited by the scarcity of recent, well-designed human trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.